News | May 05, 2010

C. R. Bard to Acquire SenoRx for $213 Million

May 5, 2010 - SenoRx Inc. announced it has entered into a definitive merger agreement with C. R. Bard at a price of $11 per share, or approximately $213 million in the aggregate.

The $11 in cash for each share that SenoRx stockholders will receive at the closing of the merger represents a 14 percent premium over the closing price on May 4, and a 41 percent premium over the company's average closing price during the 90 trading days ended May 4.

The acquisition is subject to certain closing conditions specified in the definitive agreement, including regulatory approvals and the approval of SenoRx's stockholders. The transaction is expected to close in the third quarter of 2010.

The SenoRx board of directors unanimously approved the agreement and will recommend that the company's shareholders approve the transaction.

"We believe the merger represents a great opportunity for the combined companies to create product leadership by offering a broader range of high-quality breast care products to our customers," said John Buhler, SenoRx president and CEO.

Both companies offer products for the breast and oncology market.

For more information: and

Related Content

Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
News | Brachytherapy Systems, Women's Healthcare | October 25, 2018
iCAD Inc. announced new clinical research demonstrating positive outcomes supporting the use of the Xoft Axxent...
Xoft Electronic Brachytherapy System Effective Long-Term for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 02, 2018
Breast cancer recurrence rates for patients treated with the Xoft Axxent Electronic Brachytherapy (eBx) System that...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines